Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tisagenlecleucel responses persist at 18 months in r/r B-cell ALL

Grupp SA et al. ASH 2018, Abstract 895

Key clinical point: A single infusion of tisagenlecleucel continues to demonstrate high efficacy a year and a half later in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Major finding: Among patients who had complete remission, 66% were still in remission at 18 months, while overall survival was 70% and median overall survival had not yet been reached.

Study details: A follow-up of the pivotal ELIANA trial, an international, single-arm, open-label, phase 2 study including 97 patients aged 3-24 years with relapsed or refractory B-cell acute lymphoblastic leukemia.

Disclosures: The study was supported by Novartis. Dr. Grupp reported disclosures with Novartis, Jazz Pharmaceuticals, Adaptimmune Therapeutics, and the University of Pennsylvania.

Read the article here.


Grupp SA et al. ASH 2018, Abstract 895.